Phase II trial of high-dose continuous infusion 5-fluorouracil with allopurinol modulation in colon cancer

Frederick R Ahmann, H. Garewal, B. R. Greenberg

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Twenty patients with metastatic colon cancer without prior chemotherapy received 2 g/m2 of 5-fluorouracil (5-FU) infused over 24h for 5 days preceded by allopurinol 900 mg orally for 1 week and then continued during, and for 1 week after the infusion was completed. Fourteen patients were evaluable for both response and toxicity. One patient (14%) achieved a partial response lasting 2 months. No significant hematologic toxicity was seen but 18 of 19 patients evaluable for toxicity developed mucositis resulting in dose reductions in 3 patients and refusal of a second course by 2 additional patients. 5-FU infusions with allopurinol as used in this regimen appear to offer no therapeutic advantage over a conventional dosing schedule.

Original languageEnglish (US)
Pages (from-to)83-85
Number of pages3
JournalOncology
Volume43
Issue number2
StatePublished - 1986

Fingerprint

Allopurinol
Fluorouracil
Colonic Neoplasms
Mucositis
Appointments and Schedules
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II trial of high-dose continuous infusion 5-fluorouracil with allopurinol modulation in colon cancer. / Ahmann, Frederick R; Garewal, H.; Greenberg, B. R.

In: Oncology, Vol. 43, No. 2, 1986, p. 83-85.

Research output: Contribution to journalArticle

@article{12598d3a43604496a4116f1e78973989,
title = "Phase II trial of high-dose continuous infusion 5-fluorouracil with allopurinol modulation in colon cancer",
abstract = "Twenty patients with metastatic colon cancer without prior chemotherapy received 2 g/m2 of 5-fluorouracil (5-FU) infused over 24h for 5 days preceded by allopurinol 900 mg orally for 1 week and then continued during, and for 1 week after the infusion was completed. Fourteen patients were evaluable for both response and toxicity. One patient (14{\%}) achieved a partial response lasting 2 months. No significant hematologic toxicity was seen but 18 of 19 patients evaluable for toxicity developed mucositis resulting in dose reductions in 3 patients and refusal of a second course by 2 additional patients. 5-FU infusions with allopurinol as used in this regimen appear to offer no therapeutic advantage over a conventional dosing schedule.",
author = "Ahmann, {Frederick R} and H. Garewal and Greenberg, {B. R.}",
year = "1986",
language = "English (US)",
volume = "43",
pages = "83--85",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Phase II trial of high-dose continuous infusion 5-fluorouracil with allopurinol modulation in colon cancer

AU - Ahmann, Frederick R

AU - Garewal, H.

AU - Greenberg, B. R.

PY - 1986

Y1 - 1986

N2 - Twenty patients with metastatic colon cancer without prior chemotherapy received 2 g/m2 of 5-fluorouracil (5-FU) infused over 24h for 5 days preceded by allopurinol 900 mg orally for 1 week and then continued during, and for 1 week after the infusion was completed. Fourteen patients were evaluable for both response and toxicity. One patient (14%) achieved a partial response lasting 2 months. No significant hematologic toxicity was seen but 18 of 19 patients evaluable for toxicity developed mucositis resulting in dose reductions in 3 patients and refusal of a second course by 2 additional patients. 5-FU infusions with allopurinol as used in this regimen appear to offer no therapeutic advantage over a conventional dosing schedule.

AB - Twenty patients with metastatic colon cancer without prior chemotherapy received 2 g/m2 of 5-fluorouracil (5-FU) infused over 24h for 5 days preceded by allopurinol 900 mg orally for 1 week and then continued during, and for 1 week after the infusion was completed. Fourteen patients were evaluable for both response and toxicity. One patient (14%) achieved a partial response lasting 2 months. No significant hematologic toxicity was seen but 18 of 19 patients evaluable for toxicity developed mucositis resulting in dose reductions in 3 patients and refusal of a second course by 2 additional patients. 5-FU infusions with allopurinol as used in this regimen appear to offer no therapeutic advantage over a conventional dosing schedule.

UR - http://www.scopus.com/inward/record.url?scp=0022596685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022596685&partnerID=8YFLogxK

M3 - Article

C2 - 3951789

AN - SCOPUS:0022596685

VL - 43

SP - 83

EP - 85

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2

ER -